Poseida Therapeutics, Inc. - 10-K filing on 2022-03-10

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of the Company's Stock Option Plan Activity

Following is a summary of the Company’s stock option plan activity and related information for the year ended December 31, 2021:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Intrinsic Value (thousands)
Balance at January 1, 2021		4,738,607		$	10.34		8.34
Granted		7,228,445			8.81
Exercised		(583,332	)		3.39
Forfeited/Cancelled		(1,484,013	)		10.83
Balance at December 31, 2021		9,899,707		$	9.57		8.57	$	2,938
Options vested and expected to vest as of December 31, 2021		9,899,707		$	9.57		8.57	$	2,938
Options vested and exercisable as of December 31, 2021		3,033,767		$	9.81		7.43	$	2,792

Schedule of Assumptions Used to Determine the Fair Value of Options Granted

The assumptions that the Company used to determine the fair value of options granted to employees, non-employees and directors were as follows:

	Year Ended December 31,
	2021		2020
Risk-free interest rate	0.5%–1.3%		0.4%–1.4%
Expected volatility	82.2–84.3%		79–86%
Expected term (years)	5.5–6.0		5.5–6.0
Dividend yield		—		—

Schedule of Stock-Based Compensation Expense

The Company recorded total stock-based compensation expense in the following expense categories of the accompanying consolidated statements of operations and comprehensive loss (in thousands):

	Year Ended December 31,
	2021		2020
Research and development	$	8,090	$	3,872
General and administrative		8,614		3,348
Total stock-based compensation expense	$	16,704	$	7,220